Review: lipid-lowering agents reduce cardiovascular events in type 2 diabetes.
نویسنده
چکیده
منابع مشابه
Underutilisation of cardiovascular medications among at-risk individuals
AIMS Guidelines recommend antihypertensive, lipid-lowering and/or antiplatelet therapy for prevention of cardiovascular disease (CVD). This study examined the utilisation of cardiovascular therapies among individuals at CVD risk to assess adherence to guidelines. METHODS Respondents to the SHIELD study were classified based on National Cholesterol Education Program Adult Treatment Panel III r...
متن کاملFibrates after the FIELD study: Some answers, more questions.
Fibrates have a long history in cardiovascular disease. These drugs raise high-density lipoprotein (HDL)-cholesterol, reduce triglycerides and improve small dense low-density lipoprotein (LDL) so would be expected to have large effects in type 2 diabetes, where this is the typical lipid profile. The general trial results with these agents have been confusing, with varying cardiovascular benefit...
متن کاملEffects of antidiabetic and antihyperlipidemic agents on C-reactive protein.
Type 2 diabetes mellitus (DM) increases the risk of cardiovascular disease, a major cause of morbidity and mortality. Central to type 2 DM is insulin resistance, a proinflammatory, hypercoagulable state that predisposes patients to develop cardiovascular disease and that is associated with risk factors for atherosclerosis including dyslipidemia, hypertension, inflammation, and altered hemostasi...
متن کاملCommentary on the results and clinical implications of the PROactive study.
Thiazolidinediones (TZDs), or glitazones, are a relatively new class of oral drugs that are used to treat type 2 diabetes (1–4). They lower blood glucose by targeting insulin resistance, one of the major underlying causes of the disease. In addition to their ability to lower blood glucose, TZDs also display a wide range of effects on lipids, blood pressure, weight, and other cardiovascular and ...
متن کاملGlucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes
The prevalence of type 2 diabetes mellitus is high among the elderly population. Treatment of elderly patients with type 2 diabetes presents challenges because of co-morbidities and the potential increase in the risk of adverse effects. Hyperlipidaemia is also common in the elderly population. Glucose- and lipid-lowering treatment in elderly patients should be individualized on the basis of the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- ACP journal club
دوره 141 3 شماره
صفحات -
تاریخ انتشار 2004